Novartis Stock Options

NVS Stock  USD 112.91  0.30  0.26%   
Novartis' latest option contracts expiring on April 17th 2025 are carrying combined implied volatility of 0.57 with a put-to-call open interest ratio of 1.3 over 38 outstanding agreements suggesting investors are buying more puts than calls on contracts expiring on April 17th 2025. The total put volume is at 6.0, with calls trading at the volume of 332. This yields a 0.02 put-to-call volume ratio.

Open Interest Against April 17th 2025 Option Contracts

Novartis option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Novartis' lending market. For example, when Novartis' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Novartis, he or she must hedge the risk by shorting Novartis stock over its option's life.
The chart above shows Novartis' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Novartis' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Novartis' option, there is no secondary market available for investors to trade.

Novartis Maximum Pain Price Across 2025-04-17 Option Contracts

Max pain occurs when Novartis' market makers reach a net positive position across all Novartis' options at a strike price where option holders stand to lose the most money. By contrast, Novartis' option sellers may reap the most after selling more options than buying, causing them to expire worthless.

In The Money vs. Out of Money Option Contracts on Novartis

Analyzing Novartis' in-the-money options over time can help investors to take a profitable long position in Novartis regardless of its overall volatility. This is especially true when Novartis' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Novartis' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Novartis' stock while costing only a fraction of its price.

Novartis AG ADR In The Money Call Balance

When Novartis' strike price is surpassing the current stock price, the option contract against Novartis AG ADR stock is said to be in the money. When it comes to buying Novartis' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Novartis AG ADR are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Novartis Current Options Market Mood

Novartis' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Novartis Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Novartis' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Novartis' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Novartis contract

Base on the Rule 16, the options market is currently suggesting that Novartis AG ADR will have an average daily up or down price movement of about 0.0356% per day over the life of the 2025-04-17 option contract. With Novartis trading at USD 112.91, that is roughly USD 0.0402. If you think that the market is fully incorporating Novartis' daily price movement you should consider buying Novartis AG ADR options at the current volatility level of 0.57%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing Novartis options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Novartis calls. Remember, the seller must deliver Novartis AG ADR stock to the call owner when a call is exercised.

Novartis Option Chain

When Novartis' strike price is surpassing the current stock price, the option contract against Novartis AG ADR stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Novartis' option chain is a display of a range of information that helps investors for ways to trade options on Novartis. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Novartis. It also shows strike prices and maturity days for a Novartis against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
NVS250417C001650005165.00.0 - 2.150.07Out
Call
NVS250417C0016000076160.00.0 - 2.150.05Out
Call
NVS250417C001550000155.00.0 - 2.152.15Out
Call
NVS250417C0015000021150.00.0 - 2.150.25Out
Call
NVS250417C0014500038145.00.0 - 0.450.1Out
Call
NVS250417C001400002140.00.0 - 0.21.3Out
Call
NVS250417C001350008135.00.0 - 0.20.25Out
Call
NVS250417C00130000170130.00.0 - 0.250.13Out
Call
NVS250417C00125000430125.00.1 - 0.350.35Out
Call
NVS250417C00120000514120.00.3 - 0.40.3Out
Call
NVS250417C001150003188115.01.05 - 1.251.15Out
Call
NVS250417C001100002051110.03.4 - 3.63.4In
Call
NVS250417C0010500094105.07.4 - 9.57.25In
Call
NVS250417C001000003100.010.2 - 14.29.8In
Call
NVS250417C00095000895.015.1 - 19.118.7In
Call
NVS250417C00090000290.020.2 - 22.820.6In
 Put
NVS250417P001650000165.051.9 - 55.558.18In
 Put
NVS250417P001600000160.046.5 - 50.553.1In
 Put
NVS250417P001550000155.041.8 - 45.541.8In
 Put
NVS250417P001500000150.036.5 - 40.543.29In
 Put
NVS250417P001450000145.031.5 - 35.538.14In
 Put
NVS250417P001400000140.026.5 - 30.533.19In
 Put
NVS250417P001350000135.021.5 - 25.528.3In
 Put
NVS250417P001300000130.016.5 - 20.523.1In
 Put
NVS250417P001250004125.011.6 - 15.412.9In
 Put
NVS250417P00120000204120.06.7 - 10.57.2In
 Put
NVS250417P001150001450115.04.1 - 4.44.08In
 Put
NVS250417P001100001266110.01.45 - 1.851.6Out
 Put
NVS250417P001050001521105.00.5 - 0.60.55Out
 Put
NVS250417P001000002893100.00.15 - 0.350.29Out
 Put
NVS250417P0009500072395.00.15 - 0.30.15Out
 Put
NVS250417P0009000022990.00.0 - 0.20.2Out
 Put
NVS250417P0008500027385.00.0 - 0.250.15Out
 Put
NVS250417P00080000780.00.0 - 0.20.21Out
 Put
NVS250417P00075000275.00.0 - 0.20.06Out
 Put
NVS250417P00070000370.00.0 - 0.20.05Out
 Put
NVS250417P00065000665.00.0 - 2.150.05Out
 Put
NVS250417P000600002060.00.0 - 2.150.1Out

Novartis Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

Novartis Market Cap Over Time

   Market Cap   
       Timeline  

Novartis Total Stockholder Equity

Total Stockholder Equity

56.84 Billion

At this time, Novartis' Total Stockholder Equity is comparatively stable compared to the past year.

Novartis Corporate Directors

Ton BuechnerNon-Executive Independent DirectorProfile
Frans HoutenNon-Executive Independent DirectorProfile
Nancy AndrewsNon-Executive Independent DirectorProfile
Elizabeth DohertyNon-Executive Independent DirectorProfile

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.